Albany Molecular Research, Inc. Establishes Singapore Research Centre; Company to Provide Chemical Services from a Global Platform.

ALBANY, N.Y. -- Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced that it has established a wholly owned subsidiary, Albany Molecular Research Singapore Research Centre, Pte Ltd (AMRSRC).

AMRI expects to initiate operations in Singapore in the first quarter of 2005, with the goal of providing a full range of fee-for-service chemistry technologies, including medicinal and combinatorial chemistry, process research and scale up chemistry, analytical services and cGMP manufacture of active pharmaceutical ingredients.

"AMRI's expansion into Singapore represents the first step in a strategic move to globalize our services platform," said AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. "With this initiative, we believe that we will be able to continue to provide our customers with the highest level of chemistry services over a range of competitive pricing. Further, we expect our operations in Singapore will allow us to address new markets in areas with burgeoning biotechnology and pharmaceutical industries--such as Japan, Australia and the Pacific Rim. As this initiative succeeds, we believe ultimately that a global range of options will lead to an increase in growth for AMRI's U.S.-based service operations."

D'Ambra added, "We believe that Singapore's status as a signatory to the World Patent Treaty will provide an environment in which our scientists will be able to thrive, working on cutting edge projects while retaining the intellectual property confidentiality expected by our customers. Singapore's excellent educational system, coupled with the ability to bring in highly educated employees from neighboring countries, will allow us to meet our growth objectives and maintain intellectual quality standards. Furthermore, the Singapore Government has demonstrated its commitment by investing in and designating biotechnology and healthcare as strategic industries."

"We welcome AMRI's decision to locate its research centre in Singapore. The comprehensive range of services offered by Albany will play an important role in supporting the growing base of pharmaceutical and biotechnology companies undertaking drug discovery and development in Singapore. In addition, Albany's investment reflects the international community's confidence and comfort with Singapore's legal framework for protecting intellectual property," said Mr. Philip Yeo, Chairman, Agency for Science, Technology and Research (A*STAR) and Co-Chairman, Economic Development Board (EDB) for Biomedical Sciences.

AMRI's Singapore operations will be overseen by Senior Vice President, Chemistry, Michael P. Trova, Ph.D., and led in Singapore by Assistant Director, Medicinal Chemistry Polivina Jolicia F. Gauuan, Ph.D. Three additional scientists from Albany will be relocating to Singapore to form the nucleus of AMRSRC, and they are actively recruiting in Singapore with the expectation of hiring new scientists locally in the coming months.

D'Ambra concluded, "We are excited to participate in this industrial expansion in Singapore as the first healthcare research company located there with strength in chemistry research and know-how. We especially appreciate the support provided by the Singapore Government through the Economic Development Board. Their many efforts made Singapore a logical choice for AMRI to establish offshore operations, and we look forward to working with them to create a state-of-the-art research, development and production business in Singapore."

Albany Molecular Research, Inc. is a leading research, drug discovery, development and manufacturing company built on a chemistry platform of comprehensive and integrated technologies, resources and capabilities. The company conducts research and development with many leading pharmaceutical and biotechnology companies and for its own internal discovery programs, and provides cGMP manufacturing of active pharmaceutical ingredients through its wholly owned subsidiary, Organichem Corporation. For more information, visit www.albmolecular.com.

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements regarding the establishment and growth of the company's proposed research and development operation in Singapore and the economic and other support expected to be provided to the Company from the EBD. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing chemical research and development, including continued softness in these markets, sales of Allegra (including any deviations in estimates provided by Aventis) and the company's receipt of significant royalties from the Allegra license agreement, the risk that Allegra may be approved for over-the-counter use, the over-the-counter sale of Claritin, the over-the-counter sale of generic alternatives for the treatment of allergies and the risk of new product introductions for the treatment of allergies, the integration and operating risks associated with the company's completed acquisition of Organichem, the company's ability to enforce its intellectual property and technology rights, the company's ability to successfully develop novel compounds and lead candidates in its collaborative arrangements, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions to perform as expected and any goodwill impairment related to such investments and acquisitions, the company's ability to successfully complete its ongoing expansion projects on schedule and integrate acquired companies, and the company's ability to effectively manage its growth, as well as those discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2003 as filed with the Securities and Exchange Commission on March 15, 2004, as amended by the Form 10-K/A filed on November 8, 2004. The company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release.